A nasal spray administered in high-risk adult COVID-19 patients in India reduced viral load by 94 per cent within 24 hours and 99 per cent in 48 hours, according to the results of phase 3 trial of the ...

A recent article posted to the Research Square* preprint server illustrated that early intervention with azelastine nasal spray therapy might lower the severe acute respiratory syndrome coronavirus 2 ...

Glenmark pharma’s nasal spray administered to adult Covid-19 patients showed reduction of the viral load by 94% within 24 hours and by 99% in 48 hours, according to the phase 3 trial results published ...

The trials showed that this nasal spray was safe and well tolerated by patients. No patients experienced moderate, severe, serious adverse events or death during the course of the study. Glenmark ...

VANCOUVER, British Columbia & MUMBAI, India--(BUSINESS WIRE)--SaNOtize Research & Development Corp., (“SaNOtize”), a Canadian anti-infective-focused therapeutics ...

Even as the global medical community continues to look for ways to cure and prevent Covid-19, a Mumbai-based pharmaceutical company has tested a nasal spray that has shown to effectively cure Covid-19 ...

Corona Cases In India: The number of covid cases has started increasing again; in the last 24 hours, more than 20,000 new cases have been registered, the highest after 145 days. Covid vaccination and ...

Covid Nasal Spray: A nasal spray administered in high-risk adult COVID-19 patients in India reduced viral load by 94 per cent within 24 hours and 99 per cent in 48 hours, according to the results of ...

The trial evaluated a seven-day treatment of NONS plus standard of care versus placebo nasal spray and standard care in patients with symptomatic COVID-19. (Representational image: Reuters) A nasal ...

A nasal spray administered in high-risk adult Covid-19 patients in India reduced viral load by 94 per cent within 24 hours and 99 per cent in 48 hours, according to the results of phase 3 trial of the ...